annual meeting program - American Society of Clinical Oncology

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION
Gastrointestinal (Colorectal) Cancer
Location: E Hall D1
CME credit: 3
Track(s): Gastrointestinal (Colorectal) Cancer
Sunday, June 6, 2010
Tanios S. Bekaii-Saab, MD—Co-Chair
The Ohio State University Medical Center
Chris R. Garrett, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
9:30 AM Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles
followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance
therapy in patients (pts) with metastatic colorectal cancer (mCRC): The
MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive
Tumors [TTD]). (Abstract #3501)
J. Tabernero, E. Aranda, A. Gomez, B. Massuti, J. Sastre, A. Abad, M. Valladares,
F. Rivera, M. Safont, E. Diaz-Rubio
9:45 AM Identification of potentially responsive subsets when cetuximab is added to
oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced
colorectal cancer (aCRC): Mature results of the MRC COIN trial. (Abstract
#3502)
T. S. Maughan, R. Adams, C. G. Smith, M. T. Seymour, R. H. Wilson, A. M. Meade,
D. Fisher, A. Madi, J. Cheadle, R. S. Kaplan, MRC COIN Trial Investigators
10:00 AM Final results of the EORTC intergroup randomized study 40004 (CLOCC)
evaluating the benefit of radiofrequency ablation (RFA) combined with
chemotherapy for unresectable colorectal liver metastases (CRC LM).
(Abstract #3526)
T. Ruers, C. J. Punt, F. van Coevorden, I. Borel Rinkes, J. A. Ledermann,
G. J. Poston, W. Bechstein, M. Lentz, M. Mauer, B. Nordlinger
Discussion
10:15 AM Alan Paul Venook, MD (Abstracts #3501, 3502, 3526)
University of California, San Francisco
10:30 AM Comparison of molecular and pathologic features of stage II and stage III
colon cancer in four large studies conducted for development of the 12-gene
colon cancer recurrence score. (Abstract #3503)
M. J. O’Connell, I. C. Lavery, R. G. Gray, P. Quirke, D. J. Kerr, M. Lopatin,
G. A. Yothers, M. Lee, K. Clark-Langone, N. Wolmark
10:45 AM Molecular and clinical determinants of survival following relapse after
curative treatment of stage II-III colon cancer (CC): Results of the
translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.
(Abstract #3504)
A. Roth, D. Klingbiel, P. Yan, R. Fiocca, M. Delorenzi, R. Labianca,
D. Cunningham, E. Van Cutsem, F. Bosman, S. Tejpar
11:00 AM Mutant KRAS and BRAF gene expression profiles in colorectal cancer:
Results of the translational study on the PETACC 3-EORTC 40993-SAKK
60–00 trial. (Abstract #3505)
S. Tejpar, V. Popovici, M. Delorenzi, E. Budinska, H. Estrella, M. Mao, P. Yan,
S. Weinrich, E. Van Cutsem, A. Roth
11:15 AM Cetuximab with chemotherapy (CT) as first-line treatment for metastatic
colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies
according to KRAS and BRAF mutation status. (Abstract #3506)
C. Bokemeyer, C. Kohne, P. Rougier, C. Stroh, M. Schlichting, E. Van Cutsem
229
SUNDAY